Company intelligence / Profile preview

Iktos

Paris, Franceiktos.ai ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Iktos has developed a proprietary generative AI-driven drug discovery platform that integrates molecular design, automated synthesis robotics, and high-throughput biological testing. Their in-house pipeline includes preclinical candidates targeting inflammation/autoimmune diseases, oncology, obesity/metabolism disorders, and immuno-oncology. The company claims the ability to deliver preclinical candidates in less than two years using their integrated DMTA cycle. Lead programs are currently at the preclinical candidate nomination stage; no clinical results have been reported yet.

Therapeutic areas
OncologyMetabolic DisordersImmunology
Modalities
Small molecule
Industry
Biotech
02

Drug pipeline

2 assets

SKP2-CKS1 program

Preclinical

1 more asset in the full pipeline.

03

Partnerships

Over sixty collaborations with leading pharmaceutical companies and academic institutions including strategic partnerships for drug discovery projects.M Ventures (investor)Debiopharm Innovation Fund (investor)

Beyond the preview

Go deeper on Iktos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iktos.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call